Corporate Financing

To date, Acologix has received aggregate net proceeds of $75.6 million through the placement of private equity securities. Most recently, the Company closed a Series C equity financing in December 2005 and February 2006 that raised aggregate net proceeds of $29.7 million. Funds raised in these financing rounds are being used to accelerate the Company’s leading therapeutic development programs, TRK-820, AC-100 and AC-200.